Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

Summary

The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in inflammation of the air passages. Despite appropriate treatment with oral/topical corticosteroids, saline irrigations, and surgery, nasal polyps return frequently within months of surgery. Participants will be administered a placebo or dupilumab every two weeks for 52 weeks.

Timeline

Start

2023-10-26

Primary completion

2024-07-10

Completion

2024-07-10

Outcome

Outcome not reported

Stopped (Business): “The study was terminated due to funding ending.”

Drugs

Indications